A recent study also demonstrated the effectiveness of DPP4 inhibitor sitagliptin in treating COVID-19 patients with type-2 diabetes although its mechanism of action in COVID-19 patients is not clear [22]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.